LAGging behind no more: PD-1 has a new immunotherapy partner
Immunity · 2024
DOI: 10.1016/j.immuni.2024.09.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2024. Verfasst von Andrew J Gunderson. Beteiligte Einrichtung: Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. E…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Lymphocyte Activation Gene 3 Protein, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
PD-1 blockade partially reverses T cell exhaustion in cancer patients, but broad responses are still limited. Three studies recently published in Cell illuminate how abrogating LAG-3 and PD-1 synergize to further push effector T cell functionality via distinct molecular mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. Electronic address: andrew.gunderson@osumc.edu.
Förderung
- National Cancer Institute
Zitieren
APA
Gunderson, A. J. (2024). LAGging behind no more: PD-1 has a new immunotherapy partner. Immunity. https://doi.org/10.1016/j.immuni.2024.09.010
Vancouver
Gunderson AJ. LAGging behind no more: PD-1 has a new immunotherapy partner. Immunity. 2024. doi:10.1016/j.immuni.2024.09.010
BibTeX
@article{Gunderson2024,
author = {Gunderson, Andrew J},
title = {LAGging behind no more: PD-1 has a new immunotherapy partner},
journal = {Immunity},
year = {2024},
doi = {10.1016/j.immuni.2024.09.010}
}
EUVIMED